Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy

Molecular Therapy

Volumn 18, Issue 10, 2010, Pages 1748-1757

  Frecha, Cecilia ^a,b,c,d   Lévy, Camille ^a,b,c,d   Cosset, François Loc ^a,b,c,d   Verhoeyen, Els ^a,b,c,d  

^a UNIVERSITÉ DE LYON   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE LYON   (France)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 2; INTERLEUKIN 7; LENTIVIRUS VECTOR; T LYMPHOCYTE RECEPTOR;

ADENOSINE DEAMINASE DEFICIENCY; ALLOGENIC BONE MARROW TRANSPLANTATION; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL DIVISION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; ENCEPHALOMYELITIS; GENE ACTIVATION; GENE EXPRESSION; GENETIC IMMUNIZATION; GENETIC TRANSDUCTION; HEMOPHILIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; LEUKEMIA; MEASLES VIRUS; MELANOMA; MEMORY CELL; MEMORY T LYMPHOCYTE; NONHUMAN; PHENOTYPE; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; T LYMPHOCYTE; TRANSGENE; UVEITIS; VESICULAR STOMATITIS VIRUS; VIRAL GENE THERAPY; VIRUS LOAD; WISKOTT ALDRICH SYNDROME;

MEASLES VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 77957552436     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.178     Document Type: Review

References (139)

1. Blaese, RM, Culver, KW, Miller, AD, Carter, CS, Fleisher, T, Clerici, M et al. (1995). T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science 270: 475-480.
2. Bordignon, C, Notarangelo, LD, Nobili, N, Ferrari, G, Casorati, G, Panina, P et al. (1995). Gene therapy in peripheral blood lymphocytes and bone marrow for ADAimmunodeficient patients. Science 270: 470-475.
3. Buchschacher, GL Jr and Wong-Staal, F (2001). Approaches to gene therapy for human immunodeficiency virus infection. Hum Gene Ther 12: 1013-1019.
4. Deeks, SG, Wagner, B, Anton, PA, Mitsuyasu, RT, Scadden, DT, Huang, C et al. (2002). A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther 5: 788-797.
5. Mitsuyasu, RT, Anton, PA, Deeks, SG, Scadden, DT, Connick, E, Downs, MT et al. (2000). Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 96: 785-793.
6. Recchia, A, Bonini, C, Magnani, Z, Urbinati, F, Sartori, D, Muraro, S et al. (2006). Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc Natl Acad Sci USA 103: 1457-1462.
7. Hirschhorn, R, Yang, DR, Puck, JM, Huie, ML, Jiang, CK and Kurlandsky, LE (1996). Spontaneous in vivo reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency. Nat Genet 13: 290-295. (Pubitemid 26230494)
8. Stephan, V, Wahn, V, Le Deist, F, Dirksen, U, Broker, B, M?ller-Fleckenstein, I et al. (1996). Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells. N Engl J Med 335: 1563-1567.
9. Tj?nnfjord, GE, Steen, R, Veiby, OP, Friedrich, W and Egeland, T (1994). Evidence for engraftment of donor-type multipotent CD34+ cells in a patient with selective T-lymphocyte reconstitution after bone marrow transplantation for B-SCID. Blood 84: 3584-3589.
10. Aiuti, A, Vai, S, Mortellaro, A, Casorati, G, Ficara, F, Andolfi, G et al. (2002). Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med 8: 423-425.
11. Dupré, L, Trifari, S, Follenzi, A, Marangoni, F, Lain de Lera, T, Bernad, A et al. (2004). Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction. Mol Ther 10: 903-915.
12. Martín, F, Toscano, MG, Blundell, M, Frecha, C, Srivastava, GK, Santamaría, M et al. (2005). Lentiviral vectors transcriptionally targeted to hematopoietic cells by WASP gene proximal promoter sequences. Gene Ther 12: 715-723.
13. Szydlo, R, Goldman, JM, Klein, JP, Gale, RP, Ash, RC, Bach, FH et al. (1997). Results of allogeneic bone marrow transplants for leukemia using donors other than HLAidentical siblings. J Clin Oncol 15: 1767-1777.
14. Vigorito, AC, Azevedo, WM, Marques, JF, Azevedo, AM, Eid, KA, Aranha, FJ et al. (1998). A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 22: 1145-1151.
15. Horowitz, MM, Gale, RP, Sondel, PM, Goldman, JM, Kersey, J, Kolb, HJ et al. (1990). Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75: 555-562.
16. Bonini, C, Ferrari, G, Verzeletti, S, Servida, P, Zappone, E, Ruggieri, L et al. (1997). HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versusleukemia. Science 276: 1719-1724.
17. Qasim, W, Mackey, T, Sinclair, J, Chatziandreou, I, Kinnon, C, Thrasher, AJ et al. (2007). Lentiviral vectors for T-cell suicide gene therapy: preservation of T-cell effector function after cytokine-mediated transduction. Mol Ther 15: 355-360.
18. Bondanza, A, Valtolina, V, Magnani, Z, Ponzoni, M, Fleischhauer, K, Bonyhadi, M et al. (2006). Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood 107: 1828-1836.
19. Tiberghien, P, Ferrand, C, Lioure, B, Milpied, N, Angonin, R, Deconinck, E et al. (2001). Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 97: 63-72.
20. Bobisse, S, Rondina, M, Merlo, A, Tisato, V, Mandruzzato, S, Amendola, M et al. (2009). Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors. Cancer Res 69: 9385-9394.
21. Burns, WR, Zheng, Z, Rosenberg, SA and Morgan, RA (2009). Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation. Blood 114: 2888-2899.
22. Dudley, ME, Yang, JC, Sherry, R, Hughes, MS, Royal, R, Kammula, U et al. (2008). Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26: 5233-5239.
23. Morgan, RA, Dudley, ME, Wunderlich, JR, Hughes, MS, Yang, JC, Sherry, RM et al. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
24. Stanislawski, T, Voss, RH, Lotz, C, Sadovnikova, E, Willemsen, RA, Kuball, J et al. (2001). Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2: 962-970.
25. Chun, TW, Stuyver, L, Mizell, SB, Ehler, LA, Mican, JA, Baseler, M et al. (1997). Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 94: 13193-13197.
26. Finzi, D, Hermankova, M, Pierson, T, Carruth, LM, Buck, C, Chaisson, RE et al. (1997). Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278: 1295-1300.
27. Braun, SE, Wong, FE, Connole, M, Qiu, G, Lee, L, Gillis, J et al. (2005). Inhibition of simian/human immunodeficiency virus replication in CD4+ T cells derived from lentiviral-transduced CD34+ hematopoietic cells. Mol Ther 12: 1157-1167.
28. Humeau, LM, Binder, GK, Lu, X, Slepushkin, V, Merling, R, Echeagaray, P et al. (2004). Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol Ther 9: 902-913.
29. Levine, BL, Humeau, LM, Boyer, J, MacGregor, RR, Rebello, T, Lu, X et al. (2006). Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 103: 17372-17377.
30. Wang, GP, Levine, BL, Binder, GK, Berry, CC, Malani, N, McGarrity, G et al. (2009). Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Mol Ther 17: 844-850.
31. ter Brake, O, ?t Hooft, K, Liu, YP, Centlivre, M, von Eije, KJ and Berkhout, B (2008). Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol Ther 16: 557-564.
32. Egelhofer, M, Brandenburg, G, Martinius, H, Schult-Dietrich, P, Melikyan, G, Kunert, R et al. (2004). Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol 78: 568-575.
33. Hildinger, M, Dittmar, MT, Schult-Dietrich, P, Fehse, B, Schnierle, BS, Thaler, S et al. (2001). Membrane-anchored peptide inhibits human immunodeficiency virus entry. J Virol 75: 3038-3042.
34. Chen, C, Rivera, A, Ron, N, Dougherty, JP and Ron, Y (2001). A gene therapy approach for treating T-cell-mediated autoimmune diseases. Blood 97: 886-894.
35. Lei, TC and Scott, DW (2005). Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. Blood 105: 4865-4870.
36. Melo, ME, Qian, J, El-Amine, M, Agarwal, RK, Soukhareva, N, Kang, Y et al. (2002). Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases. J Immunol 168: 4788-4795.
37. Scott, DW, Venkataraman, M and Jandinski, JJ (1979). Multiple pathways of B lymphocyte tolerance. Immunol Rev 43: 241-280.
38. Stripecke, R, Cardoso, AA, Pepper, KA, Skelton, DC, Yu, XJ, Mascarenhas, L et al. (2000). Lentiviral vectors for efficient delivery of CD80 and granulocytemacrophage- colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses. Blood 96: 1317-1326.
39. Aruffo, A, Farrington, M, Hollenbaugh, D, Li, X, Milatovich, A, Nonoyama, S et al. (1993). The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 72: 291-300.
40. Fuleihan, R, Ramesh, N, Loh, R, Jabara, H, Rosen, RS, Chatila, T et al. (1993). Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM. Proc Natl Acad Sci USA 90: 2170-2173. (Pubitemid 23078587)
41. Cantwell, M, Hua, T, Pappas, J and Kipps, TJ (1997). Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med 3: 984-989.
42. Cantwell, MJ, Sharma, S, Friedmann, T and Kipps, TJ (1996). Adenovirus vector infection of chronic lymphocytic leukemia B cells. Blood 88: 4676-4683.
43. Li, LH, Biagi, E, Allen, C, Shivakumar, R, Weiss, JM, Feller, S et al. (2006). Rapid and efficient nonviral gene delivery of CD154 to primary chronic lymphocytic leukemia cells. Cancer Gene Ther 13: 215-224.
44. Wierda, WG, Cantwell, MJ, Woods, SJ, Rassenti, LZ, Prussak, CE and Kipps, TJ (2000). CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 96: 2917-2924.
45. Moskowitz, CH (2006). Pretreatment prognostic factors and outcome in patients with relapsed or primary-refractory diffuse large B-cell lymphoma treated with secondline chemotherapy and autologous stem cell transplantation. Ann Oncol 17 Suppl 4: iv37-iv39.
46. Lei, TC, Su, Y and Scott, DW (2005). Tolerance induction via a B-cell delivered gene therapy-based protocol: optimization and role of the Ig scaffold. Cell Immunol 235: 12-20.
47. El-Amine, M, Melo, M, Kang, Y, Nguyen, H, Qian, J and Scott, DW (2000). Mechanisms of tolerance induction by a gene-transferred peptide-IgG fusion protein expressed in B lineage cells. J Immunol 165: 5631-5636.
48. Gourley, TS, Patel, DR, Nickerson, K, Hong, SC and Chang, CH (2002). Aberrant expression of Fas ligand in mice deficient for the MHC class II transactivator. J Immunol 168: 4414-4419.
49. Xu, B and Scott, DW (2004). A novel retroviral gene therapy approach to inhibit specific antibody production and suppress experimental autoimmune encephalomyelitis induced by MOG and MBP. Clin Immunol 111: 47-52.
50. Zambidis, ET, Barth, RK and Scott, DW (1997). Both resting and activated B lymphocytes expressing engineered peptide-Ig molecules serve as highly efficient tolerogenic vehicles in immunocompetent adult recipients. J Immunol 158: 2174-2182.
51. Zambidis, ET, Kurup, A and Scott, DW (1997). Genetically transferred central and peripheral immune tolerance via retroviral-mediated expression of immunogenic epitopes in hematopoietic progenitors or peripheral B lymphocytes. Mol Med 3: 212-224.
52. Zambidis, ET and Scott, DW (1996). Epitope-specific tolerance induction with an engineered immunoglobulin. Proc Natl Acad Sci USA 93: 5019-5024.
53. Agarwal, RK, Kang, Y, Zambidis, E, Scott, DW, Chan, CC and Caspi, RR (2000). Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis. J Clin Invest 106: 245-252.
54. Song, L, Wang, J, Wang, R, Yu, M, Sun, Y, Han, G et al. (2004). Retroviral delivery of GAD-IgG fusion construct induces tolerance and modulates diabetes: a role for CD4+ regulatory T cells and TGF-beta? Gene Ther 11: 1487-1496.
55. Luo, XM, Maarschalk, E, O?Connell, RM, Wang, P, Yang, L and Baltimore, D (2009). Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes. Blood 113: 1422-1431.
56. Cole, SP, Campling, BG, Atlaw, T, Kozbor, D and Roder, JC (1984). Human monoclonal antibodies. Mol Cell Biochem 62: 109-120.
57. Liao, HX, Levesque, MC, Nagel, A, Dixon, A, Zhang, R, Walter, E et al. (2009). High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J Virol Methods 158: 171-179.
58. Garet, E, Cabado, AG, Vieites, JM and González-Fernández, A (2010). Rapid isolation of single-chain antibodies by phage display technology directed against one of the most potent marine toxins: Palytoxin. Toxicon 55: 1519-1526.
59. Kwakkenbos, MJ, Diehl, SA, Yasuda, E, Bakker, AQ, van Geelen, CM, Lukens, MV et al. (2010). Generation of stable monoclonal antibody-producing B cell receptor?positive human memory B cells by genetic programming. Nat Med 16: 123-128.
60. Bhushan, A, Barnhart, B, Shone, S, Song, C and Covey, LR (2000). A transcriptional defect underlies B lymphocyte dysfunction in a patient diagnosed with non-X-linked hyper-IgM syndrome. J Immunol 164: 2871-2880.
61. White, H, Thrasher, A, Veys, P, Kinnon, C and Gaspar, HB (2000). Intrinsic defects of B cell function in X-linked severe combined immunodeficiency. Eur J Immunol 30: 732-737.
62. Vigna, E and Naldini, L (2000). Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med 2: 308-316.
63. Sutton, RE, Reitsma, MJ, Uchida, N and Brown, PO (1999). Transduction of human progenitor hematopoietic stem cells by human immunodeficiency virus type 1-based vectors is cell cycle dependent. J Virol 73: 3649-3660.
64. Kootstra, NA, Zwart, BM and Schuitemaker, H (2000). Diminished human immunodeficiency virus type 1 reverse transcription and nuclear transport in primary macrophages arrested in early G(1) phase of the cell cycle. J Virol 74: 1712-1717.
65. Neil, S, Martin, F, Ikeda, Y and Collins, M (2001). Postentry restriction to human immunodeficiency virus-based vector transduction in human monocytes. J Virol 75: 5448-5456.
66. Dardalhon, V, Jaleco, S, Kinet, S, Herpers, B, Steinberg, M, Ferrand, C et al. (2001). IL-7 differentially regulates cell cycle progression and HIV-1-based vector infection in neonatal and adult CD4+ T cells. Proc Natl Acad Sci USA 98: 9277-9282.
67. Stevenson, M, Stanwick, TL, Dempsey, MP and Lamonica, CA (1990). HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J 9: 1551-1560.
68. Sun, Y, Pinchuk, LM, Agy, MB and Clark, EA (1997). Nuclear import of HIV-1 DNA in resting CD4+ T cells requires a cyclosporin A-sensitive pathway. J Immunol 158: 512-517.
69. Zack, JA (1995). The role of the cell cycle in HIV-1 infection. Adv Exp Med Biol 374: 27-31.
70. Zack, JA, Haislip, AM, Krogstad, P and Chen, IS (1992). Incompletely reversetranscribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol 66: 1717-1725.
71. Strebel, K, Luban, J and Jeang, KT (2009). Human cellular restriction factors that target HIV-1 replication. BMC Med 7: 48.
72. Bukrinsky, MI, Sharova, N, Dempsey, MP, Stanwick, TL, Bukrinskaya, AG, Haggerty, S et al. (1992). Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc Natl Acad Sci USA 89: 6580-6584.
73. Korin, YD and Zack, JA (1998). Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J Virol 72: 3161-3168.
74. Maurice, M, Verhoeyen, E, Salmon, P, Trono, D, Russell, SJ and Cosset, FL (2002). Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide. Blood 99: 2342-2350.
75. Unutmaz, D, KewalRamani, VN, Marmon, S and Littman, DR (1999). Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J Exp Med 189: 1735-1746.
76. Ferrand, C, Robinet, E, Contassot, E, Certoux, JM, Lim, A, Hervé, P et al. (2000). Retrovirus-mediated gene transfer in primary T lymphocytes: influence of the transduction/selection process and of ex vivo expansion on the T cell receptor beta chain hypervariable region repertoire. Hum Gene Ther 11: 1151-1164.
77. Marktel, S, Magnani, Z, Ciceri, F, Cazzaniga, S, Riddell, SR, Traversari, C et al. (2003). Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood 101: 1290-1298.
78. Roth, MD (1994). Interleukin 2 induces the expression of CD45RO and the memory phenotype by CD45RA+ peripheral blood lymphocytes. J Exp Med 179: 857-864.
79. Verhoeyen, E, Dardalhon, V, Ducrey-Rundquist, O, Trono, D, Taylor, N and Cosset, FL (2003). IL-7 surface-engineered lentiviral vectors promote survival and efficient gene transfer in resting primary T lymphocytes. Blood 101: 2167-2174.
80. Fry, TJ and Mackall, CL (2001). Interleukin-7: master regulator of peripheral T-cell homeostasis? Trends Immunol 22: 564-571.
81. Geiselhart, LA, Humphries, CA, Gregorio, TA, Mou, S, Subleski, J and Komschlies, KL (2001). IL-7 administration alters the CD4:CD8 ratio, increases T cell numbers, and increases T cell function in the absence of activation. J Immunol 166: 3019-3027.
82. Rathmell, JC, Farkash, EA, Gao, W and Thompson, CB (2001). IL-7 enhances the survival and maintains the size of naive T cells. J Immunol 167: 6869-6876.
83. Cavalieri, S, Cazzaniga, S, Geuna, M, Magnani, Z, Bordignon, C, Naldini, L et al. (2003). Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood 102: 497-505.
84. Ducrey-Rundquist, O, Guyader, M and Trono, D (2002). Modalities of interleukin-7- induced human immunodeficiency virus permissiveness in quiescent T lymphocytes. J Virol 76: 9103-9111.
85. Swainson, L, Verhoeyen, E, Cosset, FL and Taylor, N (2006). IL-7R alpha gene expression is inversely correlated with cell cycle progression in IL-7-stimulated T lymphocytes. J Immunol 176: 6702-6708.
86. Verhoeyen, E, Costa, C and Cosset, FL (2009). Lentiviral vector gene transfer into human T cells. In: Baum, C (ed). Genetic Modification of Hematopoietic Stem Cells Methods and Protocols, vol.506. Humana Press: New York. pp 97-114.
87. Bovia, F, Salmon, P, Matthes, T, Kvell, K, Nguyen, TH, Werner-Favre, C et al. (2003). Efficient transduction of primary human B lymphocytes and nondividing myeloma B cells with HIV-1-derived lentiviral vectors. Blood 101: 1727-1733.
88. Janssens, W, Chuah, MK, Naldini, L, Follenzi, A, Collen, D, Saint-Remy, JM et al. (2003). Efficiency of onco-retroviral and lentiviral gene transfer into primary mouse and human B-lymphocytes is pseudotype dependent. Hum Gene Ther 14: 263-276.
89. Serafini, M, Naldini, L and Introna, M (2004). Molecular evidence of inefficient transduction of proliferating human B lymphocytes by VSV-pseudotyped HIV-1- derived lentivectors. Virology 325: 413-424.
90. Chinnasamy, D, Chinnasamy, N, Enriquez, MJ, Otsu, M, Morgan, RA and Candotti, F (2000). Lentiviral-mediated gene transfer into human lymphocytes: role of HIV-1 accessory proteins. Blood 96: 1309-1316.
91. Grima?tre, M, Werner-Favre, C, Kindler, V and Zubler, RH (1997). Human naive B cells cultured with EL-4 T cells mimic a germinal center-related B cell stage before generating plasma cells. Concordant changes in Bcl-2 protein and messenger RNA levels. Eur J Immunol 27: 199-205.
92. Matthes, T, Werner-Favre, C, Tang, H, Zhang, X, Kindler, V and Zubler, RH (1993). Cytokine mRNA expression during an in vitro response of human B lymphocytes: kinetics of B cell tumor necrosis factor alpha, interleukin (IL)6, IL-10, and transforming growth factor beta 1 mRNAs. J Exp Med 178: 521-528.
93. Tucci, A, James, H, Chicheportiche, R, Bonnefoy, JY, Dayer, JM and Zubler, RH (1992). Effects of eleven cytokines and of IL-1 and tumor necrosis factor inhibitors in a human B cell assay. J Immunol 148: 2778-2784.
94. Kvell, K, Nguyen, TH, Salmon, P, Glauser, F, Werner-Favre, C, Barnet, M et al. (2005). Transduction of CpG DNA-stimulated primary human B cells with bicistronic lentivectors. Mol Ther 12: 892-899.
95. Lizée, G, Gonzales, MI and Topalian, SL (2004). Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells. Hum Gene Ther 15: 393-404.
96. Funke, S, Maisner, A, M?hlebach, MD, Koehl, U, Grez, M, Cattaneo, R et al. (2008). Targeted cell entry of lentiviral vectors. Mol Ther 16: 1427-1436.
97. Yang, L, Bailey, L, Baltimore, D and Wang, P (2006). Targeting lentiviral vectors to specific cell types in vivo. Proc Natl Acad Sci USA 103: 11479-11484.
98. Ziegler, L, Yang, L, Joo, K, Yang, H, Baltimore, D and Wang, P (2008). Targeting lentiviral vectors to antigen-specific immunoglobulins. Hum Gene Ther 19: 861-872.
99. Straub, C and Zubler, RH (1989). Immortalization of EBV-infected B cells is not influenced by exogenous signals acting on B cell proliferation. Effects of mutant EL-4 thymoma cells and transforming growth factor-beta. J Immunol 142: 87-93.
100. Fecteau, JF, Roy, A and Néron, S (2009). Peripheral blood CD27+ IgG+ B cells rapidly proliferate and differentiate into immunoglobulin-secreting cells after exposure to low CD154 interaction. Immunology 128(1 Suppl): e353-e365.
101. Cragg, MS, Walshe, CA, Ivanov, AO and Glennie, MJ (2005). The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 8: 140-174.
102. Glennie, MJ, French, RR, Cragg, MS and Taylor, RP (2007). Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 44: 3823-3837.
103. Buchholz, CJ, M?hlebach, MD and Cichutek, K (2009). Lentiviral vectors with measles virus glycoproteins ? dream team for gene transfer? Trends Biotechnol 27: 259-265.
104. Hatziioannou, T, Delahaye, E, Martin, F, Russell, SJ and Cosset, FL (1999). Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin. Hum Gene Ther 10: 1533-1544.
105. Morizono, K, Bristol, G, Xie, YM, Kung, SK and Chen, IS (2001). Antibody-directed targeting of retroviral vectors via cell surface antigens. J Virol 75: 8016-8020.
106. Sandrin, V, Boson, B, Salmon, P, Gay, W, N?gre, D, Le Grand, R et al. (2002). Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 100: 823-832.
107. Liang, M, Morizono, K, Pariente, N, Kamata, M, Lee, B and Chen, IS (2009). Targeted transduction via CD4 by a lentiviral vector uses a clathrin-mediated entry pathway. J Virol 83: 13026-13031.
108. Schnierle, BS, Stitz, J, Bosch, V, Nocken, F, Merget-Millitzer, H, Engelst?dter, M et al. (1997). Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells. Proc Natl Acad Sci USA 94: 8640-8645.
109. Sch?le, S, Steidl, S, Panitz, S, Coulibaly, C, Kalinke, U, Cichutek, K et al. (2006). Selective gene transfer to T lymphocytes using coreceptor-specific [MLV(HIV)] pseudotype vectors in a transgenic mouse model. Virology 351: 237-247.
110. Moreau, T, Bardin, F, Imbert, J, Chabannon, C and Tonnelle, C (2004). Restriction of transgene expression to the B-lymphoid progeny of human lentivirally transduced CD34+ cells. Mol Ther 10: 45-56.
111. Taher, TE, Tulone, C, Fatah, R, D?Acquisto, F, Gould, DJ and Mageed, RA (2008). Repopulation of B-lymphocytes with restricted gene expression using haematopoietic stem cells engineered with lentiviral vectors. Gene Ther 15: 998-1006.
112. Laurie, KL, Blundell, MP, Baxendale, HE, Howe, SJ, Sinclair, J, Qasim, W et al. (2007). Cell-specific and efficient expression in mouse and human B cells by a novel hybrid immunoglobulin promoter in a lentiviral vector. Gene Ther 14: 1623-1631.
113. Marodon, G, Mouly, E, Blair, EJ, Frisen, C, Lemoine, FM and Klatzmann, D (2003). Specific transgene expression in human and mouse CD4+ cells using lentiviral vectors with regulatory sequences from the CD4 gene. Blood 101: 3416-3423.
114. D?rig, RE, Marcil, A, Chopra, A and Richardson, CD (1993). The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 75: 295-305.
115. Santiago, C, Celma, ML, Stehle, T and Casasnovas, JM (2010). Structure of the measles virus hemagglutinin bound to the CD46 receptor. Nat Struct Mol Biol 17: 124-129.
116. Tatsuo, H, Ono, N, Tanaka, K and Yanagi, Y (2000). SLAM (CDw150) is a cellular receptor for measles virus. Nature 406: 893-897.
117. Frecha, C, Costa, C, N?gre, D, Gauthier, E, Russell, SJ, Cosset, FL et al. (2008). Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins. Blood 112: 4843-4852.
118. Frecha, C, Costa, C, Lévy, C, N?gre, D, Russell, SJ, Maisner, A et al. (2009). Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors. Blood 114: 3173-3180.
119. Lévy, C, Frecha, C, Costa, C, Rachinel, N, Salles, G, Cosset, FL et al. (2010). Lentiviral vectors and transduction of human cancer B cells. Blood 116: 498-500; author reply 500.
120. Pierson, TC, Zhou, Y, Kieffer, TL, Ruff, CT, Buck, C and Siliciano, RF (2002). Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J Virol 76: 8518-8531.
121. Zhou, Y, Zhang, H, Siliciano, JD and Siliciano, RF (2005). Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells. J Virol 79: 2199-2210.
122. Vatakis, DN, Bristol, G, Wilkinson, TA, Chow, SA and Zack, JA (2007). Immediate activation fails to rescue efficient human immunodeficiency virus replication in quiescent CD4+ T cells. J Virol 81: 3574-3582.
123. Korin, YD and Zack, JA (1999). Nonproductive human immunodeficiency virus type 1 infection in nucleoside-treated G0 lymphocytes. J Virol 73: 6526-6532.
124. Plesa, G, Dai, J, Baytop, C, Riley, JL, June, CH and O?Doherty, U (2007). Addition of deoxynucleosides enhances human immunodeficiency virus type 1 integration and 2LTR formation in resting CD4+ T cells. J Virol 81: 13938-13942.
125. Coil, DA and Miller, AD (2004). Phosphatidylserine is not the cell surface receptor for vesicular stomatitis virus. J Virol 78: 10920-10926.
126. Sun, X, Yau, VK, Briggs, BJ and Whittaker, GR (2005). Role of clathrin-mediated endocytosis during vesicular stomatitis virus entry into host cells. Virology 338: 53-60.
127. Vatakis, DN, Kim, S, Kim, N, Chow, SA and Zack, JA (2009). Human immunodeficiency virus integration efficiency and site selection in quiescent CD4+ T cells. J Virol 83: 6222-6233.
128. Agosto, LM, Yu, JJ, Liszewski, MK, Baytop, C, Korokhov, N, Humeau, LM et al. (2009). The CXCR4-tropic human immunodeficiency virus envelope promotes more-efficient gene delivery to resting CD4+ T cells than the vesicular stomatitis virus glycoprotein G envelope. J Virol 83: 8153-8162.
129. Santoni de Sio, FR, Cascio, P, Zingale, A, Gasparini, M and Naldini, L (2006). Proteasome activity restricts lentiviral gene transfer into hematopoietic stem cells and is down-regulated by cytokines that enhance transduction. Blood 107: 4257-4265.
130. Bouche, FB, Ertl, OT and Muller, CP (2002). Neutralizing B cell response in measles. Viral Immunol 15: 451-471.
131. Naniche, D (2009). Human immunology of measles virus infection. Curr Top Microbiol Immunol 330: 151-171.
132. Circosta, P, Granziero, L, Follenzi, A, Vigna, E, Stella, S, Vallario, A et al. (2009). T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR. Hum Gene Ther 20: 1576-1588.
133. Neagu, MR, Ziegler, P, Pertel, T, Strambio-De-Castillia, C, Gr?tter, C, Martinetti, G et al. (2009). Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components. J Clin Invest 119: 3035-3047.
134. Sakuma, R, Noser, JA, Ohmine, S and Ikeda, Y (2007). Inhibition of HIV-1 replication by simian restriction factors, TRIM5alpha and APOBEC3G. Gene Ther 14: 185-189.
135. Werner-Favre, C, Bovia, F, Schneider, P, Holler, N, Barnet, M, Kindler, V et al. (2001). IgG subclass switch capacity is low in switched and in IgM-only, but high in IgD+IgM+, post-germinal center (CD27+) human B cells. Eur J Immunol 31:243-249.
136. Agosto, LM, Yu, JJ, Dai, J, Kaletsky, R, Monie, D and O?Doherty, U (2007). HIV-1 integrates into resting CD4+ T cells even at low inoculums as demonstrated with an improved assay for HIV-1 integration. Virology 368: 60-72.
137. Dardalhon, V, Herpers, B, Noraz, N, Pflumio, F, Guetard, D, Leveau, C et al. (2001). Lentivirus-mediated gene transfer in primary T cells is enhanced by a central DNA flap. Gene Ther 8: 190-198.
138. Swiggard, WJ, Baytop, C, Yu, JJ, Dai, J, Li, C, Schretzenmair, R et al. (2005). Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J Virol 79: 14179-14188.
139. Swiggard, WJ, O?Doherty, U, McGain, D, Jeyakumar, D and Malim, MH (2004). Long HIV type 1 reverse transcripts can accumulate stably within resting CD4+ T cells while short ones are degraded. AIDS Res Hum Retroviruses 20: 285-295.